{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T11:03:22Z","timestamp":1788692602305,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>By evaluating published emulations of oncology randomized control trial (RCT) studies in which both the active and comparator groups are sourced from real-world data (RWD) and target trial results are available for benchmarking, this systematic review aims to gain insight into factors related to emulation performance. Thirteen oncology emulation studies using various types of RWD were identified through an online database search of PubMed through 2022. Based on the ROBINS-I tool, most studies (n\u00a0=\u00a08) had a serious risk of overall bias driven by risk of bias from confounding. Approximately half of the studies (n\u00a0=\u00a06) fully proxied the RCT entry criteria. Of 11 RWD studies that provided sufficient detail to quantify emulation performance, the emulation hazard ratio (HR) estimate fell within the 95% confidence interval (CI) of the trial estimate in 9 of the studies. There were no clear trends between risk of bias or degree to which the entry criteria were proxied and emulation performance. Findings may have been influenced by publication bias and researcher degrees of freedom, as only one emulation study preregistered its protocol. Tools for comprehensively characterizing factors that affect emulation performance, including the real-world clinical context as it relates to the RCT research question, are needed to evaluate the feasibility of a RCT emulation.<\/jats:p>\n               <jats:p>This article is part of a Special Collection on Pharmacoepidemiology.<\/jats:p>","DOI":"10.1093\/aje\/kwae346","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:55:57Z","timestamp":1725584157000},"page":"1783-1793","source":"Crossref","is-referenced-by-count":9,"title":["Emulations of oncology trials using real-world data: a systematic literature review"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-6036","authenticated-orcid":false,"given":"Jennifer R","family":"Rider","sequence":"first","affiliation":[{"name":"Aetion, Inc. , New York, NY 10001 ,","place":["United States"]},{"name":"ConcertAI, 1120 Massachusetts Avenue, Cambridge, MA 02138 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Wasserman","sequence":"additional","affiliation":[{"name":"xCures, Inc. , Oakland, CA 94612 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Slipski","sequence":"additional","affiliation":[{"name":"ConcertAI, 1120 Massachusetts Avenue, Cambridge, MA 02138 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillis","family":"Carrigan","sequence":"additional","affiliation":[{"name":"Center for Observational Research, Amgen , San Francisco, CA 94080 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Harvey","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Brisbane , CA 94005 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Jiao","sequence":"additional","affiliation":[{"name":"Bayer Pharmaceuticals , Whippany, NJ 07981 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"McRoy","sequence":"additional","affiliation":[{"name":"Pfizer , New York City, NY 10001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson D","family":"Pace","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago, IL 60064 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Becnel","sequence":"additional","affiliation":[{"name":"Pfizer , New York City, NY 10001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Bruno","sequence":"additional","affiliation":[{"name":"Bayer Pharmaceuticals , Whippany, NJ 07981 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy C","family":"Eckert","sequence":"additional","affiliation":[{"name":"Reagan-Udall Foundation for the Food and Drug Administration , Washington, DC 20036 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Hodgkins","sequence":"additional","affiliation":[{"name":"Aetion, Inc. , New York, NY 10001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva","family":"Jain","sequence":"additional","affiliation":[{"name":"Aetion, Inc. , New York, NY 10001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Merola","sequence":"additional","affiliation":[{"name":"Aetion, Inc. , New York, NY 10001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osayi E","family":"Ovbiosa","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago, IL 60064 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Natanzon","sequence":"additional","affiliation":[{"name":"ConcertAI, 1120 Massachusetts Avenue, Cambridge , MA 02138,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago, IL 60064 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameson","family":"Quinn","sequence":"additional","affiliation":[{"name":"xCures, Inc. , Oakland, CA 94612 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Rodriguez-Watson","sequence":"additional","affiliation":[{"name":"Reagan-Udall Foundation for the Food and Drug Administration , Washington, DC 20036 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka","family":"Campbell","sequence":"additional","affiliation":[{"name":"Aetion, Inc. , New York, NY 10001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Coalition to Advance RWE in RCT Emulations (CARE) Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"2025060320125997100_ref1","volume-title":"Framework for FDA's Real World Evidence Program","author":"US Food and Drug Administration","year":"2018"},{"issue":"10","key":"2025060320125997100_ref2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","article-title":"Use of real-world evidence to support FDA approval of oncology drugs","volume":"23","author":"Feinberg","year":"2020","journal-title":"Value Health."},{"issue":"10","key":"2025060320125997100_ref3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies","volume":"143","author":"Franklin","year":"2021","journal-title":"Circulation."},{"key":"2025060320125997100_ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"2025060320125997100_ref5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.urology.2020.01.039","article-title":"Emulating target clinical trials of radical nephrectomy with or without lymph node dissection for renal cell carcinoma","volume":"140","author":"Bacic","year":"2020","journal-title":"Urology."},{"issue":"1","key":"2025060320125997100_ref6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.eururo.2008.09.052","article-title":"Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of cancer (EORTC) randomized phase 3 trial 30881","volume":"55","author":"Blom","year":"2009","journal-title":"Eur Urol."},{"issue":"6","key":"2025060320125997100_ref7","doi-asserted-by":"publisher","first-page":"274.e15","DOI":"10.1016\/j.urolonc.2022.02.002","article-title":"Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder","volume":"40","author":"Bharadwaj","year":"2022","journal-title":"Urol Oncol."},{"issue":"1","key":"2025060320125997100_ref8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3\u2013pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"2025060320125997100_ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3587","article-title":"Association of a shortened duration of adjuvant chemotherapy with overall survival among individuals with stage III colon cancer","volume":"4","author":"Boyne","year":"2021","journal-title":"JAMA Netw Open."},{"issue":"13","key":"2025060320125997100_ref10","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med."},{"key":"2025060320125997100_ref11","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00195","article-title":"Simulating colorectal cancer trials using real-world data","volume":"6","author":"Chen","year":"2022","journal-title":"JCO Clin Cancer Inform."},{"issue":"14","key":"2025060320125997100_ref12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Eric","year":"2009","journal-title":"N Engl J Med."},{"issue":"24","key":"2025060320125997100_ref13","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","article-title":"Analysis of KRAS \/ NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2025060320125997100_ref14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ejca.2015.03.003","article-title":"Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study","volume":"51","author":"Garcia-Albeniz","year":"2015","journal-title":"Eur J Cancer."},{"issue":"6","key":"2025060320125997100_ref15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, nonblinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol."},{"issue":"7","key":"2025060320125997100_ref16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/cer-2021-0224","article-title":"Bridging the gap between oncology clinical trials and real-world data: evidence on replicability of efficacy results using German claims data","volume":"11","author":"Ghiani","year":"2022","journal-title":"J Comp Eff Res."},{"issue":"8","key":"2025060320125997100_ref17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med."},{"issue":"6","key":"2025060320125997100_ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18371","article-title":"Temporal trends in clinical evidence of 5-year survival within electronic health records among patients with early-stage colon cancer managed with laparoscopy-assisted colectomy vs open colectomy","volume":"5","author":"Hou","year":"2022","journal-title":"JAMA Netw Open."},{"issue":"20","key":"2025060320125997100_ref19","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1056\/NEJMoa032651","article-title":"A comparison of laparoscopically assisted and open colectomy for colon cancer","volume":"350","author":"Nelson","year":"2004","journal-title":"N Engl J Med."},{"issue":"20","key":"2025060320125997100_ref20","doi-asserted-by":"publisher","first-page":"13560","DOI":"10.3390\/ijerph192013560","article-title":"Carfilzomib\u2019s real-world safety outcomes in Korea: target trial emulation study using electronic health records","volume":"19","author":"Jang","year":"2022","journal-title":"Int J Environ Res Public Health."},{"issue":"21","key":"2025060320125997100_ref21","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med."},{"key":"2025060320125997100_ref22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jclinepi.2022.10.005","article-title":"Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: systematic bias assessment of ovarian cancer treatment effectiveness","volume":"152","author":"Kuehne","year":"2022","journal-title":"J Clin Epidemiol."},{"issue":"9747","key":"2025060320125997100_ref23","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet."},{"issue":"2","key":"2025060320125997100_ref24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/cpt.2443","article-title":"Real-world overall survival using oncology electronic health record data: friends of cancer research pilot","volume":"111","author":"Lasiter","year":"2022","journal-title":"Clin Pharmacol Ther."},{"issue":"22","key":"2025060320125997100_ref25","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"2025060320125997100_ref26","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac049","article-title":"Real-world evidence prediction of a phase IV oncology trial: comparative Degarelix vs leuprolide safety","volume":"6","author":"Merola","year":"2022","journal-title":"JNCI Cancer Spectr."},{"issue":"16","key":"2025060320125997100_ref27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of Degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation."},{"issue":"4","key":"2025060320125997100_ref28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/pds.5565","article-title":"Effectiveness research in oncology with electronic health record data: a retrospective cohort study emulating the PALOMA -2 trial","volume":"32","author":"Merola","year":"2023","journal-title":"Pharmacoepidemiol Drug."},{"issue":"20","key":"2025060320125997100_ref29","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med."},{"key":"2025060320125997100_ref30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2147\/CLEP.S373291","article-title":"Oncology drug effectiveness from electronic health record data calibrated against RCT evidence: the PARSIFAL trial emulation","volume":"14","author":"Merola","year":"2022","journal-title":"Clin Epidemiol."},{"issue":"12","key":"2025060320125997100_ref31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","article-title":"Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor\u2013positive, ERBB2-negative advanced breast cancer: a randomized clinical trial","volume":"7","author":"Llombart-Cussac","year":"2021","journal-title":"JAMA Oncol."},{"key":"2025060320125997100_ref32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in nonrandomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"issue":"6","key":"2025060320125997100_ref33","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/cpt.2883","article-title":"A structured process to identify fit-for-purpose study design and data to generate valid and transparent real-world evidence for regulatory uses","volume":"113","author":"Gatto","year":"2023","journal-title":"Clin Pharmacol Ther."},{"issue":"8","key":"2025060320125997100_ref34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol."},{"issue":"4","key":"2025060320125997100_ref35","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/cpt.1793","article-title":"Emulation differences vs. biases when calibrating real-world evidence findings against randomized controlled trials","volume":"107","author":"Franklin","year":"2020","journal-title":"Clin Pharmacol Ther."}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwae346\/59066735\/kwae346.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/6\/1783\/59066735\/kwae346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/6\/1783\/59066735\/kwae346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:13:03Z","timestamp":1748995983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/194\/6\/1783\/7754121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,9,9]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwae346","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,9,9]]}}}